Our Communication format is ideally suited to short studies - which can be preliminary in nature - that are of such importance that they require accelerated publication.
Communications must contain original and highly significant work whose interest to the RSC Pharmaceutics readership and high novelty warrants rapid publication. Authors should supply with their submission a justification of why the work merits urgent publication as a Communication. Referees will be asked to judge the work on these grounds.
Communications are given high visibility within the journal as they are published at the front of an issue. Communications will not normally exceed the length of five printed journal pages.
Full papers in RSC Pharmaceutics present original research that has not been published previously. Although there is no page limit for Full papers, appropriateness of length to content of new science will be taken into consideration.
Reviews, Perspectives & Opinions
These are normally commissioned by the editorial board and editorial office, although suggestions are most welcome – proposals (comprising the title, short synopsis, and key references) should be sent by email to the Editors at RSCPharmafirstname.lastname@example.org.
Reviews, Perspectives and Opinions must be high-quality, authoritative, state-of-the-art accounts of a particular facet of pharmaceutics or pharmaceutical technology. They should be timely and add to the existing literature, rather than duplicate existing articles, and should be easily comprehensible and of general interest to the journal's wide readership. All Reviews, Perspectives and Opinions undergo a rigorous and full peer review procedure, in the same way as regular research papers.
All review content should consist of original text and interpretation, avoiding any direct reproduction. If a significant amount of other people's material is to be used, either textual or image-based, permission must be sought by the author in accordance with copyright law and must be made clear in the manuscript.
Review articles report a detailed, balanced and authoritative current account of the selected research field. Please note that Reviews in RSC Pharmaceutics may not contain any original research.
Perspectives are contributions offering the personal account or critical analysis of a topic of current interest. They present a state-of-the-art account with an emphasis on future challenges and opportunities. Perspectives may contain some unpublished research and have no strict length requirements, and they should be written to their natural length.
Opinions provide a short, personal viewpoint or hypothesis on a topic of current interest to the scientific community. They can be speculative in nature and stimulate counter-opinion, provided that they are not defamatory to the work of others. They should contain rigorous, evidence-backed scientific justification, and bring significant and valuable insights to the field.
Comments and Replies are a medium for the discussion and exchange of scientific opinions between authors and readers concerning material published in RSC Pharmaceutics.
For publication, a Comment should present an alternative analysis of and/or new insight into the previously published material. Any Reply should further the discussion presented in the original article and the Comment. Comments and Replies that contain any form of personal attack are not suitable for publication.
Comments that are acceptable for publication will be forwarded to the authors of the work being discussed, and these authors will be given the opportunity to submit a Reply. The Comment and Reply will both be subject to rigorous peer review in consultation with the journal’s Editorial Board where appropriate. The Comment and Reply will be published together.